Alnylam Pharmaceuticals Inc. (ALNY)

81.02
1.90 2.40
NASDAQ : Health Technology
Prev Close 79.14
Open 79.53
Day Low/High 79.49 / 81.43
52 Wk Low/High 60.27 / 96.08
Volume 245.36K
Avg Volume 717.00K
Exchange NASDAQ
Shares Outstanding 111.21M
Market Cap 8.78B
EPS -7.60
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Alnylam To Webcast Presentation At 2019 Cantor Global Healthcare Conference

Alnylam To Webcast Presentation At 2019 Cantor Global Healthcare Conference

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the 2019 Cantor Global Healthcare Conference on Thursday, October 3, 2019 at 9:30 am ET at the...

Alnylam Pharmaceuticals Announces Initiation Of APOLLO-B Phase 3 Study Of Patisiran For The Treatment Of Transthyretin Amyloidosis With Cardiomyopathy

Alnylam Pharmaceuticals Announces Initiation Of APOLLO-B Phase 3 Study Of Patisiran For The Treatment Of Transthyretin Amyloidosis With Cardiomyopathy

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the Company has initiated APOLLO-B, a global Phase 3 placebo-controlled clinical trial of patisiran, an intravenously administered RNAi therapeutic,...

Alnylam Presents New Evidence Demonstrating Significant Association Of V122I, A Highly Prevalent, Pathogenic Transthyretin (TTR) Mutation, With Clinical Diagnosis Of Polyneuropathy

Alnylam Presents New Evidence Demonstrating Significant Association Of V122I, A Highly Prevalent, Pathogenic Transthyretin (TTR) Mutation, With Clinical Diagnosis Of Polyneuropathy

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today presented new results from an analysis of the UK Biobank - a prospective cohort study with genetic, physical, and health data on approximately 500,000 individuals...

1,000 Alnylam Employees Across The Globe Volunteer At 5th Annual Community Service Day

1,000 Alnylam Employees Across The Globe Volunteer At 5th Annual Community Service Day

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, yesterday gave back to the communities where Alnylam employees live and work at its fifth annual company-wide "Helping Hands" Community Service Day.

Alnylam Presents New Clinical Results For Givosiran At The 2019 International Congress On Porphyrins And Porphyrias

Alnylam Presents New Clinical Results For Givosiran At The 2019 International Congress On Porphyrins And Porphyrias

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the Company and its collaborators presented new clinical results at the 2019 International Congress on Porphyrins and Porphyrias (ICPP), held...

Alnylam To Host Sixth Annual "RNAi Roundtable" Webcast Series

Alnylam To Host Sixth Annual "RNAi Roundtable" Webcast Series

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it plans to kick off its 6 th annual series of "RNAi Roundtable" webcasts over the coming weeks.

Alnylam Presents New Clinical Research Findings At The Second European Meeting Of ATTR Amyloidosis For Doctors And Patients

Alnylam Presents New Clinical Research Findings At The Second European Meeting Of ATTR Amyloidosis For Doctors And Patients

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today shared new findings at the Second European Meeting of ATTR Amyloidosis (EU-ATTR) for Doctors and Patients, being held September 2-3, in Berlin, Germany.

Alnylam Pharmaceuticals Provides Perspective On Positive Complete Results From ORION-11 Phase 3 Study Of Inclisiran

Alnylam Pharmaceuticals Provides Perspective On Positive Complete Results From ORION-11 Phase 3 Study Of Inclisiran

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today provided perspective on the positive complete results from the ORION-11 Phase 3 study of inclisiran, an RNAi therapeutic in development for the treatment of...

Alnylam To Webcast Presentation At 17th Annual Morgan Stanley Global Healthcare Conference

Alnylam To Webcast Presentation At 17th Annual Morgan Stanley Global Healthcare Conference

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the 17 th Annual Morgan Stanley Global Healthcare Conference on Monday, September 9, 2019 at 10:30 am...

Alnylam To Report New Clinical Results For Givosiran At The 2019 International Congress On Porphyrins And Porphyrias

Alnylam To Report New Clinical Results For Givosiran At The 2019 International Congress On Porphyrins And Porphyrias

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the Company and its collaborators will present at the 2019 International Congress on Porphyrins and Porphyria (ICPP), being held September 8-11, 2019...

Ironwood Pharmaceuticals And Alnylam Pharmaceuticals Enter U.S. GI Disease Education And Promotional Agreement For Alnylam's Givosiran In Acute Hepatic Porphyria (AHP)

Ironwood Pharmaceuticals And Alnylam Pharmaceuticals Enter U.S. GI Disease Education And Promotional Agreement For Alnylam's Givosiran In Acute Hepatic Porphyria (AHP)

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), the leading RNAi therapeutics company and Ironwood Pharmaceuticals, Inc.

Alnylam Pharmaceuticals And Ironwood Pharmaceuticals Enter U.S. GI Disease Education And Promotional Agreement For Alnylam's Givosiran In Acute Hepatic Porphyria (AHP)

Alnylam Pharmaceuticals And Ironwood Pharmaceuticals Enter U.S. GI Disease Education And Promotional Agreement For Alnylam's Givosiran In Acute Hepatic Porphyria (AHP)

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), the leading RNAi therapeutics company and Ironwood Pharmaceuticals, Inc.

Alnylam Pharmaceuticals Reports Second Quarter 2019 Financial Results And Highlights Recent Period Activity

Alnylam Pharmaceuticals Reports Second Quarter 2019 Financial Results And Highlights Recent Period Activity

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the second quarter 2019 and reviewed recent business highlights.

Alnylam Announces U.S. Food And Drug Administration (FDA) Granted Priority Review Of The Givosiran New Drug Application (NDA) For The Treatment Of Acute Hepatic Porphyria

Alnylam Announces U.S. Food And Drug Administration (FDA) Granted Priority Review Of The Givosiran New Drug Application (NDA) For The Treatment Of Acute Hepatic Porphyria

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the U.

Alnylam To Webcast Conference Call Discussing Second Quarter 2019 Financial Results

Alnylam To Webcast Conference Call Discussing Second Quarter 2019 Financial Results

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter ending June 30, 2019 on Tuesday, August 6, 2019, before the U.

Alnylam Launches ONPATTRO® (patisiran) For The Treatment Of Polyneuropathy In HATTR Amyloidosis, The First-Ever RNAi Therapeutic Approved In Canada

Alnylam Launches ONPATTRO® (patisiran) For The Treatment Of Polyneuropathy In HATTR Amyloidosis, The First-Ever RNAi Therapeutic Approved In Canada

ONPATTRO ®  is the Only Treatment that Demonstrated Improvement, Relative to Baseline, in both Polyneuropathy and Quality of Life Measures in Patients 1, 2 with hATTR Amyloidosis MISSISSAUGA, ON, July 23, 2019 /CNW/ -  Alnylam Pharmaceuticals, Inc.

Alnylam And 23andMe Collaborate On MyFamily Program To Increase Awareness Of TTR-Related Hereditary Amyloidosis

Alnylam And 23andMe Collaborate On MyFamily Program To Increase Awareness Of TTR-Related Hereditary Amyloidosis

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, and 23andMe, the leading consumer genetics company, are collaborating on a program to offer free 23andMe Health + Ancestry kits to first-degree family members of 23andMe...

Alnylam Pharmaceuticals Announces Transition Of Chief Financial Officer

Alnylam Pharmaceuticals Announces Transition Of Chief Financial Officer

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that Jeff Poulton is joining the Company on July 11, 2019 and has been appointed Executive Vice President and Chief Financial Officer (CFO), effective...

Alnylam Submits Marketing Authorization Application To The European Medicines Agency For Givosiran For The Treatment Of Acute Hepatic Porphyria

Alnylam Submits Marketing Authorization Application To The European Medicines Agency For Givosiran For The Treatment Of Acute Hepatic Porphyria

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, today announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for givosiran, an investigational RNAi therapeutic...

Alnylam Presents New ONPATTRO® (patisiran) Results At The 2019 Peripheral Nerve Society Annual Meeting

Alnylam Presents New ONPATTRO® (patisiran) Results At The 2019 Peripheral Nerve Society Annual Meeting

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today new results from the Global Open-Label Extension (OLE) study of ONPATTRO ® (patisiran), an RNAi therapeutic for the treatment of the polyneuropathy of...

Alnylam Announces Progress With RNAi Therapeutics Platform, Including Oral Route Of Administration And CNS And Ocular Delivery

Alnylam Announces Progress With RNAi Therapeutics Platform, Including Oral Route Of Administration And CNS And Ocular Delivery

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today new advances in its RNAi therapeutics platform, including preclinical results demonstrating oral delivery of GalNAc-conjugated small interfering RNAs...

Alnylam Announces Approval In Japan Of ONPATTRO® For The Treatment Of Hereditary ATTR Amyloidosis With Polyneuropathy

Alnylam Announces Approval In Japan Of ONPATTRO® For The Treatment Of Hereditary ATTR Amyloidosis With Polyneuropathy

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved ONPATTRO ® (patisiran) for the treatment of hereditary transthyretin-mediated...

Alnylam Completes Enrollment For ILLUMINATE-A Phase 3 Study Of Lumasiran In Patients With Primary Hyperoxaluria Type 1 (PH1)

Alnylam Completes Enrollment For ILLUMINATE-A Phase 3 Study Of Lumasiran In Patients With Primary Hyperoxaluria Type 1 (PH1)

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, announced today that it has achieved full patient enrollment in its ILLUMINATE-A Phase 3 study of lumasiran, an investigational RNAi therapeutic targeting glycolate...

Alnylam To Report New Clinical Results For ONPATTRO® (patisiran) At Peripheral Nerve Society (PNS) Annual Meeting And The 5th Congress Of The European Academy Of Neurology (EAN)

Alnylam To Report New Clinical Results For ONPATTRO® (patisiran) At Peripheral Nerve Society (PNS) Annual Meeting And The 5th Congress Of The European Academy Of Neurology (EAN)

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the Company will present new results from the Global Open-Label Extension (OLE) study of ONPATTRO ® (patisiran) in patients with hereditary ATTR...

Alnylam Completes Rolling Submission Of New Drug Application To U.S. Food And Drug Administration (FDA) For Givosiran For The Treatment Of Acute Hepatic Porphyria

Alnylam Completes Rolling Submission Of New Drug Application To U.S. Food And Drug Administration (FDA) For Givosiran For The Treatment Of Acute Hepatic Porphyria

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today the completion of the rolling submission of a New Drug Application (NDA) to the U.

Alnylam Doses First Patient In Phase 1 Study Of ALN-AGT, An Investigational RNAi Therapeutic For The Treatment Of Hypertension

Alnylam Doses First Patient In Phase 1 Study Of ALN-AGT, An Investigational RNAi Therapeutic For The Treatment Of Hypertension

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the first patient has been dosed in the Company's Phase 1 study of ALN-AGT, an investigational RNAi therapeutic targeting angiotensinogen (AGT) for...

Alnylam To Webcast Presentations At Upcoming June Investor Conferences

Alnylam To Webcast Presentations At Upcoming June Investor Conferences

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences: Jefferies 2019 Global Healthcare Conference on Friday, June 7, 2019 at 10:30...

Alnylam Announces New Leadership Appointments

Alnylam Announces New Leadership Appointments

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today the appointment of Kelley Boucher as the Company's Senior Vice President (SVP), Chief Human Resources Officer (CHRO) and the promotion of Kevin...